Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease …

Background Plasma glial fibrillary acidic protein (GFAP) has emerged as a promising
biomarker in neurological disorders, but further evidence is required in relation to its …

Introduction Plasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation
and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer's disease …

Background: Measuring plasma glial fibrillary acidic protein (GFAP) alongside cortical
amyloid-β (Aβ) may shed light on astrocytic changes in aging and Alzheimer's disease (AD) …

Introduction Recent evidence has shown that the marker of reactive astrogliosis, glial
fibrillary acidic protein (GFAP), has a stronger relationship with cerebral amyloid beta (Aβ) …

Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in
blood samples, and has been associated with Alzheimer's disease (AD). However, plasma …

Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured
astroglial GFAP in patients with AD (n= 28), frontotemporal dementia (bvFTD, n= 35) …

Glial fibrillary acidic protein (GFAP) has been suggested as a biomarker for reactive
astrogliosis. We measured the levels of plasma GFAP by Simoa in 60 patients with PD with …

Biomarkers in the cerebrospinal fluid (CSF) are currently regarded as indispensable
indicators for accurate differential diagnosis of neurodegenerative disorders. Although high …

Objective Reactive astrogliosis is a hallmark of Alzheimer's disease (AD) and frontotemporal
dementia (FTD) but differences between the diseases and time course are unclear. Here, we …